Relapsed Acute Myeloid Leukemia Clinical Trials

7 recruiting

Frequently Asked Questions

Common questions about Relapsed Acute Myeloid Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Acute Leukemia of Ambiguous LineageRefractory Acute Myeloid LeukemiaRelapsed Acute Myeloid Leukemia
St. Jude Children's Research Hospital24 enrolled10 locationsNCT06177067
Recruiting
Phase 1

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

Acute Myeloid LeukemiaAcute Myeloid Leukemia, in RelapseRefractory Acute Myeloid Leukemia+2 more
Memorial Sloan Kettering Cancer Center15 enrolled7 locationsNCT06017258
Recruiting
Phase 1

Imetelstat Combinations in Relapsed AML

Relapsed Acute Myeloid Leukemia
Douglas Tremblay36 enrolled1 locationNCT07320235
Recruiting
Phase 1Phase 2

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Acute Myeloid LeukemiaMixed Phenotype Acute LeukemiaRefractory Acute Myeloid Leukemia+10 more
University of Washington62 enrolled1 locationNCT04797767
Recruiting
Phase 1Phase 2

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

Refractory Acute Myeloid LeukemiaRelapsed Acute Myeloid Leukemia
Stanford University20 enrolled1 locationNCT06561152
Recruiting
Phase 2

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML

AMLRefractory Acute Myeloid LeukemiaRelapsed Acute Myeloid Leukemia
Beijing 302 Hospital20 enrolled1 locationNCT06741722
Recruiting
Phase 2

VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS

Minimal Residual DiseaseMyelodysplastic SyndromesRefractory Acute Myeloid Leukemia+1 more
Beijing 302 Hospital67 enrolled1 locationNCT06536959